Knoa Drug Patent Portfolio
Knoa owns 5 orange book drugs protected by 104 US patents with Butrans having the least patent protection, holding only 6 patents. And Hysingla Er with maximum patent protection, holding 42 patents. Given below is the list of Knoa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11857547 | Compositions and methods for opioid antagonist delivery | 05 Nov, 2039 | Active |
| US11865112 | Compositions and methods for opioid antagonist delivery | 05 Nov, 2039 | Active |
| US10722473 | Methods and compositions particularly for treatment of attention deficit disorder | 19 Nov, 2038 | Active |
| US10111839 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10292938 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10292939 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10449159 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10500162 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10507186 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10512612 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10512613 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10568841 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US10688060 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US9974752 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
| US11191908 | Syringe shock absorber for use in an injection device | 18 Oct, 2035 | Active |
| US11813435 | Needle assisted injection device having reduced trigger force | 25 Feb, 2035 | Active |
| US10881798 | Needle assisted injection device having reduced trigger force | 11 Feb, 2034 | Active |
| US8808740 | Encased tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
| US9572779 | Encased tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
| US9750703 | Encased tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
| US9861584 | Tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
| US9872837 | Tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
| US11185642 | Injection device with cammed ram assembly | 28 Aug, 2031 | Active |
| US10357609 | Needle assisted jet injection device having reduced trigger force | 21 Aug, 2031 | Active |
| US10905827 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
| US11446440 | Needle assisted injection device having reduced trigger force | 21 Aug, 2031 | Active |
| US8496619 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
| US9364610 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
| US9364611 | Needle assisted jet injection device having reduced trigger force | 21 Aug, 2031 | Active |
| US9446195 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
| US10279131 | Injection device with cammed RAM assembly | 31 Jul, 2031 | Active |
| US8894987 | Tamper resistant dosage forms | 29 Mar, 2030 | Active |
| US11304908 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US11304909 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9084816 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9095614 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9095615 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9486412 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9486413 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9492389 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9492390 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9492391 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9545380 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9763933 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9770416 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9775809 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US11964056 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US12246094 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US12280152 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US8808741 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US8894988 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9492392 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9492393 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US9775808 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
| US8021335 | Prefilled syringe jet injector | 04 Oct, 2026 | Active |
| US10478560 | Prefilled syringe injector | 24 Jan, 2026 | Expired |
| US11446441 | Prefilled syringe injector | 24 Jan, 2026 | Expired |
| US8562564 | Prefilled syringe jet injector | 24 Jan, 2026 | Expired |
| US9180259 | Prefilled syringe jet injector | 24 Jan, 2026 | Expired |
| US9533102 | Prefilled syringe jet injector | 24 Jan, 2026 | Expired |
| US9629959 | Prefilled syringe jet injector | 24 Jan, 2026 | Expired |
| US7776314 | Abuse-proofed dosage system | 19 Apr, 2025 | Expired |
| US10407434 | Process for preparing oxycodone compositions | 30 Mar, 2025 | Expired |
| US10696684 | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US12060361 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US9522919 | Oxycodone compositions | 30 Mar, 2025 | Expired |
| US11844865 | Abuse-proofed oral dosage form | 13 Feb, 2025 | Expired |
| US8114383 | Abuse-proofed dosage form | 10 Oct, 2024 | Expired |
| US10130591 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US8309060 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US10675278 | Crush resistant delayed-release dosage forms | 20 Nov, 2023 | Expired |
| US10369109 | Abuse-proofed dosage form | 16 Jun, 2023 | Expired |
| US9675610 | Abuse-proofed dosage form | 16 Jun, 2023 | Expired |
| US8529948 | Pharmaceutical formulation containing gelling agent | 06 Aug, 2022 | Expired |
| US8337888 | Pharmaceutical formulation containing gelling agent | 06 Aug, 2022 | Expired |
| US9060976 | Pharmaceutical formulation containing gelling agent | 06 Aug, 2022 | Expired |
| US6733783 | Controlled release hydrocodone formulations | 30 Oct, 2021 | Expired |
| US8361499 | Controlled release hydrocodone formulations | 30 Oct, 2021 | Expired |
| US8551520 | Controlled release hydrocodone | 30 Oct, 2021 | Expired |
| US8647667 | Controlled release hydrocodone formulations | 30 Oct, 2021 | Expired |
| US9023401 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9056052 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9060940 | Controlled release hydrocodone | 30 Oct, 2020 | Expired |
| US9198863 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9205056 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9289391 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9517236 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9572804 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9669023 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9669024 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
| US9675611 | Methods of providing analgesia | 30 Oct, 2020 | Expired |
| US9682077 | Methods of providing analgesia | 30 Oct, 2020 | Expired |
| US9642850 | Method of providing sustained analgesia with buprenorphine | 29 Sep, 2017 | Expired |
| USRE41408 | Method of providing sustained analgesia with buprenorpine | 29 Sep, 2017 | Expired |
| USRE41489 | Method of providing sustained analgesia with buprenorphine | 29 Sep, 2017 | Expired |
| USRE41571 | Method of providing sustained analgesia with buprenorphine | 29 Sep, 2017 | Expired |
| US6488963 | Hot-melt extrudable pharmaceutical formulation | 24 Jun, 2017 | Expired |
| US6264980 | Transdermal resorption of active substances from supercooled masses of levulic acid | 18 Dec, 2015 | Expired |
| US6344211 | Transdermal absorption of active substances from subcooled melts | 18 Dec, 2015 | Expired |
| US5508042 | Controlled release oxycodone compositions | 16 Apr, 2013 | Expired |
Latest Legal Activities on Knoa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Knoa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 10 Nov, 2025 | US8551520 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Oct, 2025 | US9974752 |
| Expire Patent | 13 Oct, 2025 | US8529948 (Litigated) |
| Maintenance Fee Reminder Mailed | 29 Sep, 2025 | US8647667 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2025 | US11304909 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2025 | US11304908 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2025 | US11304909 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2025 | US11304908 |
| Expire Patent | 28 Jul, 2025 | US9682077 |
| Expire Patent | 21 Jul, 2025 | US9675610 |
| Expire Patent | 21 Jul, 2025 | US9675610 |
| Expire Patent | 14 Jul, 2025 | US9669023 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2025 | US9872837 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2025 | US9861584 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Jun, 2025 | US11191908 |
Knoa's Drug Patent Litigations
Knoa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 11, 2016, against patent number US9060976. The petitioner Amneal Pharmaceuticals, LLC, challenged the validity of this patent, with PURDUE PHARMA L.P. et al. as the respondent. Click below to track the latest information on how companies are challenging Knoa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9492392 | February, 2018 |
Terminated-Settled
(21 Aug, 2018)
| Purdue Pharma L.P. | Kashiv Pharma, LLC |
| US9492393 | February, 2018 |
Terminated-Settled
(21 Aug, 2018)
| Purdue Pharma L.P. | Kashiv Pharma, LLC |
| US9060976 | May, 2016 |
Final Written Decision
(08 Nov, 2017)
| PURDUE PHARMA L.P. et al. | Amneal Pharmaceuticals, LLC |
Knoa Drug Patents' Oppositions Filed in EPO
Knoa drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP19150366A | Sep, 2022 | Bandpay & Greuter | Granted and Under Opposition |
| EP06719329A | Oct, 2019 | Bandpay & Greuter | Patent maintained as amended |
| EP06706682A | Dec, 2017 | G. L. Pharma GmbH | Revoked |
| EP11186168A | Oct, 2016 | James Poole Limited | Opposition rejected |
| EP10011792A | Oct, 2015 | Hoffmann Eitle | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | Setna, Rohan P. | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | James Poole Limited | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | Acino Pharma AG | Granted and Under Opposition |
| EP05730345A | Dec, 2011 | Actavis group PTC ehf | Patent maintained as amended |
| EP05730345A | Dec, 2011 | Acino Pharma AG | Patent maintained as amended |
| EP05730345A | Dec, 2011 | Elend, Almut Susanne | Patent maintained as amended |
| EP2005006983W | Oct, 2009 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP2005006983W | Oct, 2009 | Ypsomed AG | Patent maintained as amended |
| EP04763833A | Mar, 2008 | Purdue Pharma LP | Opposition rejected |
| EP04763834A | Dec, 2007 | Purdue Pharma LP | Opposition rejected |
Knoa's Family Patents
Knoa drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 28.5% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Knoa Drug List
Given below is the complete list of Knoa's drugs and the patents protecting them.
1. Adhansia Xr
Adhansia Xr is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10722473 | Methods and compositions particularly for treatment of attention deficit disorder |
19 Nov, 2038
(12 years from now)
| Active |
| US10111839 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10292938 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10292939 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10449159 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10500162 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10507186 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10512612 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10512613 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10568841 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US10688060 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
| US9974752 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adhansia Xr's drug page
2. Butrans
Butrans is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9642850 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(8 years ago)
| Expired |
| USRE41408 | Method of providing sustained analgesia with buprenorpine |
29 Sep, 2017
(8 years ago)
| Expired |
| USRE41489 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(8 years ago)
| Expired |
| USRE41571 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(8 years ago)
| Expired |
| US6264980 | Transdermal resorption of active substances from supercooled masses of levulic acid |
18 Dec, 2015
(10 years ago)
| Expired |
| US6344211 | Transdermal absorption of active substances from subcooled melts |
18 Dec, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Butrans's drug page
3. Hysingla Er
Hysingla Er is protected by 42 patents, out of which 23 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8808740 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(5 years from now)
| Active |
| US9572779 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(5 years from now)
| Active |
| US9750703 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(5 years from now)
| Active |
| US9861584 | Tamper resistant controlled release dosage forms |
21 Dec, 2031
(5 years from now)
| Active |
| US9872837 | Tamper resistant controlled release dosage forms |
21 Dec, 2031
(5 years from now)
| Active |
| US11304908 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US11304909 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9084816 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9095614 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9095615 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9486412 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9486413 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492389 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492390 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492391 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9545380 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9763933 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9770416 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9775809 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US11844865 | Abuse-proofed oral dosage form |
13 Feb, 2025
(1 year, 4 months ago)
| Expired |
| US10130591 | Abuse-proofed dosage form |
20 Nov, 2023
(2 years ago)
| Expired |
| US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(2 years ago)
| Expired |
| US10369109 | Abuse-proofed dosage form |
16 Jun, 2023
(3 years ago)
| Expired |
| US9675610 | Abuse-proofed dosage form |
16 Jun, 2023
(3 years ago)
| Expired |
| US8529948 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(3 years ago)
| Expired |
| US6733783 | Controlled release hydrocodone formulations |
30 Oct, 2021
(4 years ago)
| Expired |
| US8361499 | Controlled release hydrocodone formulations |
30 Oct, 2021
(4 years ago)
| Expired |
| US8551520 | Controlled release hydrocodone |
30 Oct, 2021
(4 years ago)
| Expired |
| US8647667 | Controlled release hydrocodone formulations |
30 Oct, 2021
(4 years ago)
| Expired |
| US9023401 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9056052 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9060940 | Controlled release hydrocodone |
30 Oct, 2020
(5 years ago)
| Expired |
| US9198863 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9205056 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9289391 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9517236 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9572804 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9669023 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9669024 | Controlled release hydrocodone formulations |
30 Oct, 2020
(5 years ago)
| Expired |
| US9675611 | Methods of providing analgesia |
30 Oct, 2020
(5 years ago)
| Expired |
| US9682077 | Methods of providing analgesia |
30 Oct, 2020
(5 years ago)
| Expired |
| US6488963 | Hot-melt extrudable pharmaceutical formulation |
24 Jun, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hysingla Er's drug page
4. Oxycontin
Oxycontin is protected by 34 patents, out of which 19 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8894987 | Tamper resistant dosage forms |
29 Mar, 2030
(3 years from now)
| Active |
| US11304908 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US11304909 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US11964056 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US12246094 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US12280152 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US8808741 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US8894988 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492389 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492391 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492392 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9492393 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9763933 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9770416 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US9775808 | Tamper resistant dosage forms |
24 Aug, 2027
(1 year, 2 months from now)
| Active |
| US7776314 | Abuse-proofed dosage system |
19 Apr, 2025
(1 year, 1 month ago)
| Expired |
| US10407434 | Process for preparing oxycodone compositions |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US10696684 | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US12060361 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US9522919 | Oxycodone compositions |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US8114383 | Abuse-proofed dosage form |
10 Oct, 2024
(1 year, 8 months ago)
| Expired |
| US10130591 | Abuse-proofed dosage form |
20 Nov, 2023
(2 years ago)
| Expired |
| US10675278 | Crush resistant delayed-release dosage forms |
20 Nov, 2023
(2 years ago)
| Expired |
| US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(2 years ago)
| Expired |
| US10369109 | Abuse-proofed dosage form |
16 Jun, 2023
(3 years ago)
| Expired |
| US9675610 | Abuse-proofed dosage form |
16 Jun, 2023
(3 years ago)
| Expired |
| US8337888 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(3 years ago)
| Expired |
| US9060976 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(3 years ago)
| Expired |
| US6488963 | Hot-melt extrudable pharmaceutical formulation |
24 Jun, 2017
(8 years ago)
| Expired |
| US5508042 | Controlled release oxycodone compositions |
16 Apr, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxycontin's drug page
5. Zurnai (autoinjector)
Zurnai (autoinjector) is protected by 21 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11857547 | Compositions and methods for opioid antagonist delivery |
05 Nov, 2039
(13 years from now)
| Active |
| US11865112 | Compositions and methods for opioid antagonist delivery |
05 Nov, 2039
(13 years from now)
| Active |
| US11191908 | Syringe shock absorber for use in an injection device |
18 Oct, 2035
(9 years from now)
| Active |
| US11813435 | Needle assisted injection device having reduced trigger force |
25 Feb, 2035
(8 years from now)
| Active |
| US10881798 | Needle assisted injection device having reduced trigger force |
11 Feb, 2034
(7 years from now)
| Active |
| US11185642 | Injection device with cammed ram assembly |
28 Aug, 2031
(5 years from now)
| Active |
| US10357609 | Needle assisted jet injection device having reduced trigger force |
21 Aug, 2031
(5 years from now)
| Active |
| US10905827 | Injection device with cammed ram assembly |
21 Aug, 2031
(5 years from now)
| Active |
| US11446440 | Needle assisted injection device having reduced trigger force |
21 Aug, 2031
(5 years from now)
| Active |
| US8496619 | Injection device with cammed ram assembly |
21 Aug, 2031
(5 years from now)
| Active |
| US9364610 | Injection device with cammed ram assembly |
21 Aug, 2031
(5 years from now)
| Active |
| US9364611 | Needle assisted jet injection device having reduced trigger force |
21 Aug, 2031
(5 years from now)
| Active |
| US9446195 | Injection device with cammed ram assembly |
21 Aug, 2031
(5 years from now)
| Active |
| US10279131 | Injection device with cammed RAM assembly |
31 Jul, 2031
(5 years from now)
| Active |
| US8021335 | Prefilled syringe jet injector |
04 Oct, 2026
(3 months from now)
| Active |
| US10478560 | Prefilled syringe injector |
24 Jan, 2026
(4 months ago)
| Expired |
| US11446441 | Prefilled syringe injector |
24 Jan, 2026
(4 months ago)
| Expired |
| US8562564 | Prefilled syringe jet injector |
24 Jan, 2026
(4 months ago)
| Expired |
| US9180259 | Prefilled syringe jet injector |
24 Jan, 2026
(4 months ago)
| Expired |
| US9533102 | Prefilled syringe jet injector |
24 Jan, 2026
(4 months ago)
| Expired |
| US9629959 | Prefilled syringe jet injector |
24 Jan, 2026
(4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurnai (autoinjector)'s drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List